Работы, цитирующие эту работу

Работ: 2

Работа: Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)

1. The Use of Nivolumab in Colorectal Cancer with Lynch Syndrome. A Case Report

   G. G. Khakimova, A. Tryakin, G.A. Khakimov Khakimov

   СтатьяGenetic factors in colorectal cancerMalignant tumours2020Цитирований: 0

   ABIABI:AkademIndex/openalex/2020.article.001794

2. Molecular mechanisms of colorectal cancer formation and their significance (literature review)

   Navruzov Sn, Behzod Navruzov, S. T. Rakhmonov +4

   СтатьяGenetic factors in colorectal cancerSurgery and Oncology2024Цитирований: 0

   ABIABI:AkademIndex/openalex/2024.article.004397